Stockscreener 앱 받기
4.16
2.35%
-0.10
Relay Therapeutics Inc 주식(RLAY)의 최신 뉴스
Intrahepatic Cholangiocarcinoma Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics - The Globe and Mail
Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Relay Therapeutics Inc (RLAY) Volatility Hits 7.89% – Here Is What You Should Do - Stocks Register
Relay Therapeutics stock hits 52-week low at $4.25 By Investing.com - Investing.com Canada
Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 100,000 Shares - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Reaches New 1-Year LowHere's What Happened - MarketBeat
Relay Therapeutics CEO Sanjiv Patel sells $500,000 in stock - Investing.com
Relay Therapeutics CEO Sanjiv Patel sells $500,000 in stock By Investing.com - Investing.com UK
Relay Therapeutics stock hits 52-week low at $4.25 - Investing.com
HighTower Advisors LLC Cuts Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by HighTower Advisors LLC - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 5.4%Time to Sell? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.58 Million Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Relay Therapeutics: A Hidden Gem in Cancer Treatment with RLY-2608's Potential to Revolutionize Breast Cancer Care - mediahousepress
Relay Therapeutics' SWOT analysis: stock's potential in PI3K inhibitor race By Investing.com - Investing.com Australia
Relay Therapeutics' SWOT analysis: stock's potential in PI3K inhibitor race - Investing.com India
Relay Therapeutics’ (RLAY) Market Outperform Rating Reiterated at JMP Securities - Defense World
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - MSN
Relay Therapeutics stock holds Buy rating, BofA highlights $1bn+ peak sales potential for RLY-2608 - Investing.com Nigeria
Relay Therapeutics' (RLAY) Market Outperform Rating Reiterated at JMP Securities - MarketBeat
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival - Marketscreener.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
Layoff Tracker: Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff - BioSpace
Relay Therapeutics Announces Updated Interim Data for - GlobeNewswire
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival - GlobeNewswire Inc.
Frustrated by IRA, Relay out-licenses ‘NDA-ready’ program to Elevar - BioCentury
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - The Manila Times
Relay Therapeutics to Present Updated Clinical Data on - GlobeNewswire
Elevar Therapeutics’ Global Licensing Agreement with Relay Therapeutics - Global Legal Chronicle
1,349,400 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Bought by Point72 Asset Management L.P. - MarketBeat
FY2024 Earnings Forecast for RLAY Issued By Leerink Partnrs - MarketBeat
HC Wainwright Predicts Lower Earnings for Relay Therapeutics - MarketBeat
Leerink Partners Cuts Relay Therapeutics (NASDAQ:RLAY) Price Target to $18.00 - Defense World
Leerink Partnrs Has Positive Outlook of RLAY FY2024 Earnings - Defense World
Relay Therapeutics price target lowered to $18 from $19 at Leerink - MSN
After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY) - Yahoo Finance
Why Relay Therapeutics (RLAY) is the Best All-Time Low Stock to Buy Right Now? - Insider Monkey
Elevar nabs Relay’s FGFR2 rare cancer drug in $500M deal - BioWorld Online
Relay Therapeutics stock sees target decrease, strong potential for lirafugratinib - Investing.com
Relay Therapeutics stock target cut by Leerink amid licensing agreement - Investing.com UK
Maven Securities LTD Takes $2.39 Million Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics stock hits 52-week low at $4.48 By Investing.com - Investing.com South Africa
Relay Therapeutics stock hits 52-week low at $4.48 - Investing.com
Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - The Manila Times
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - GlobeNewswire
Relay Therapeutics Has Interesting Science That Needs To Be Proven In Trials (NASDAQ:RLAY) - Seeking Alpha
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by Bellevue Group AG - MarketBeat
Braidwell LP Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Eventide Asset Management LLC Acquires Shares of 2,682,083 Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Walleye Capital LLC Acquires 1,793,057 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Sio Capital Management LLC Buys New Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
2.88%
2.65%
자본화:
|
볼륨(24시간):